The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Genetic Validation of the Protein Arginine Methyltransferase PRMT5 as a Candidate Therapeutic Target in Glioblastoma
Open accessPublished version of a preprint
Abstract
Glioblastoma is the most common and aggressive histologic subtype of brain cancer with poor outcomes and limited treatment options. Here, we report the selective overexpression of the protein arginine methyltransferase PRMT5 as a novel candidate theranostic target in this disease. PRMT5 silences the transcription of regulatory genes by catalyzing symmetric dimethylation of arginine residues on histone tails. PRMT5 overexpression in patient-derived primary tumors and cell lines correlated with cell line growth rate and inversely with overall patient survival. Genetic attenuation of PRMT5 led to cell-cycle arrest, apoptosis, and loss of cell migratory activity. Cell death was p53-independent but caspase-dependent and enhanced with temozolomide, a chemotherapeutic agent used as a present standard of care. Global gene profiling and chromatin immunoprecipitation identified the tumor suppressor ST7 as a key gene silenced by PRMT5. Diminished ST7 expression was associated with reduced patient survival. PRMT5 attenuation limited PRMT5 recruitment to the ST7 promoter, led to restored expression of ST7 and cell growth inhibition. Finally, PRMT5 attenuation enhanced glioblastoma cell survival in a mouse xenograft model of aggressive glioblastoma. Together, our findings defined PRMT5 as a candidate prognostic factor and therapeutic target in glioblastoma, offering a preclinical justification for targeting PRMT5-driven oncogenic pathways in this deadly disease. Cancer Res; 74(6); 1752–65. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similar to the context-dependent function of histone methyltransferases, the dynamic association of lysine demethylases with multi-protein complexes governs their stability and substrate specificity 180 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [180]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Self-citationWen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316
WALKER, M. D., Green, S. B., Byar, D. P., Alexander, E., Batzdorf, U., Brooks, W. H., Hunt, W. E., MacCarty, C. S., Mahaley, M. S., Mealey, J., et al. (1980) · New England Journal of Medicine · doi:10.1056/nejm198012043032303 · Cited by 1,618
The Bcl-2 family: roles in cell survival and oncogenesis
Cory, S., Huang, D. C. S., & Adams, J. M. (2003) · Oncogene · doi:10.1038/sj.onc.1207102 · Cited by 1,474
Genetic Pathways to Glioblastoma
Ohgaki, H., Dessen, P., Jourde, B., Horstmann, S., Nishikawa, T., Patre, P.-L. D., Burkhard, C., Schüler, D., Probst-Hensch, N. M., Maiorka, P. C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1337 · Cited by 1,306
Control of mitochondrial apoptosis by the Bcl-2 family
Brunelle, J. K., & Letai, A. G. (2009) · Journal of Cell Science · doi:10.1242/jcs.031682 · Cited by 928
Pal, S., Vishwanath, S. N., Erdjument‐Bromage, H., Tempst, P., & Sif, S. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.21.9630-9645.2004 · Cited by 599
Self-citationZhao, Q., Rank, G., Tan, Y., Li, H., Moritz, R. L., Simpson, R. J., Cerruti, L., Curtis, D. J., Patel, D. J., Allis, C. D., et al. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1568 · Cited by 539
Cited by
Sorted by citations
Arginine Methylation: The Coming of Age
Blanc, R. S., & Richard, S. (2017) · Molecular Cell · doi:10.1016/j.molcel.2016.11.003 · Cited by 1,054
Histone Modifications and CancerPreprint
Audia, J. E., & Campbell, R. M. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019521 · Cited by 1,060
The roles of DNA, RNA and histone methylation in ageing and cancer
Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0143-1 · Cited by 549
The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond
Stopa, N., Krebs, J. E., & Shechter, D. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1847-9 · Cited by 529
MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 axis
Marjon, K., Cameron, M. J., Quang, P., Clasquin, M. F., Mandley, E., Kunii, K., McVay, M., Choe, S., Kernytsky, A., Gross, S., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.043 · Cited by 485
Protein arginine methylation: from enigmatic functions to therapeutic targeting
Wu, Q., Schapira, M., Arrowsmith, C. H., & Baršytė-Lovejoy, D. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00159-8 · Cited by 462
Chemical Biology of Protein Arginine Modifications in Epigenetic Regulation
Fuhrmann, J., Clancy, K. W., & Thompson, P. R. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00003 · Cited by 325
Protein arginine methyltransferases: promising targets for cancer therapy
Hwang, J. W., Cho, Y., Bae, G., Kim, S., & Kim, Y. K. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00613-y · Cited by 290
Glioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
PRMT5 inhibition disrupts splicing and stemness in glioblastoma
Sachamitr, P., Ho, J. C., Ciamponi, F. E., Ba-Alawi, W., Coutinho, F. J., Guilhamon, P., Kushida, M. M., Cavalli, F. M. G., Lee, L., Rastegar, N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21204-5 · Cited by 227
Gerhart, S. V., Kellner, W. A., Thompson, C., Pappalardi, M. B., Zhang, X.-P., Oca, R. M. D., Chan-Penebre, E., Duncan, K. W., Boriack-Sjodin, A., Le, B., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28002-y · Cited by 216
Self-citationChen, H., Lorton, B. M., Gupta, V., & Shechter, D. (2016) · Oncogene · doi:10.1038/onc.2016.205 · Cited by 188
Deng, X., Shao, G. Q., Zhang, H.-T., Li, C., Zhang, D., Cheng, L., Elzey, B. D., Пили, Р., Ratliff, T. L., Huang, J., et al. (2016) · Oncogene · doi:10.1038/onc.2016.287 · Cited by 169
Self-citationPRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers
Li, Y., Chitnis, N., Nakagawa, H., Kita, Y., Natsugoe, S., Yang, Y., Li, Z., Wasik, M., Klein-Szanto, A. J. P., Rustgi, A. K., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0625 · Cited by 143
Banasavadi‐Siddegowda, Y., Russell, L., Frair, E. C., Karkhanis, V. A., Relation, T., Yoo, J. Y., Zhang, J., Sif, S., Imitola, J., Baiocchi, R. A., et al. (2016) · Oncogene · doi:10.1038/onc.2016.199 · Cited by 137
Self-citationDong, F., Li, Q., Yang, C., Huo, D., Wang, X., Ai, C., Kong, Y., Sun, X., Wang, W., Zhou, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06968-7 · Cited by 121
Self-citationProtein arginine methyltransferase 5 (PRMT5) dysregulation in cancer
Shailesh, H., Zakaria, Z. Z., Baiocchi, R. A., & Sif, S. (2018) · Oncotarget · doi:10.18632/oncotarget.26404 · Cited by 115
Self-citationProtein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery
Wang, Y., Hu, W., & Yuan, Y. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00598 · Cited by 114
Targeting post-translational histone modifying enzymes in glioblastoma
Kunadis, E., Lakiotaki, E., Korkolopoulou, P. A., & Piperi, C. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107721 · Cited by 113
Rugo, H. S., Jacobs, I. A., Sharma, S., Scappaticci, F. A., Paul, T. A., Jensen-Pergakes, K., & Malouf, G. G. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01379-x · Cited by 109
Discovery of First-in-Class Protein Arginine Methyltransferase 5 (PRMT5) Degraders
Shen, Y., Gao, G., Yu, X., Kim, H., Wang, L., Xie, L., Schwarz, M. C., Chen, X., Guccione, E., Liu, J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01111 · Cited by 107
Zhang, B., Dong, S., Zhu, R., Hu, C., Hou, J., Li, Y., Zhao, Q., Shao, X., Bu, Q., Li, H., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4332 · Cited by 104
PRMT5 as a druggable target for glioblastoma therapy
Banasavadi‐Siddegowda, Y., Welker, A. M., An, M. J., Yang, X. T., Zhou, W., Shi, G., Imitola, J., Li, C., Hsu, S. H., Wang, J., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox206 · Cited by 108
Self-citationRole of protein arginine methyltransferase 5 in human cancers
Xiao, W., Chen, X., Liu, L., Shu, Y., Zhang, M., & Zhong, Y. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108790 · Cited by 100
Burgos, E. S., Wilczek, C., Onikubo, T., Bonanno, J. B., Jansong, J., Reimer, U., & Shechter, D. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.636894 · Cited by 99
Discovery of a Dual PRMT5–PRMT7 Inhibitor
Smil, D. V., Eram, M. S., Li, F., Kennedy, S., Szewczyk, M. M., Brown, P. J., Baršytė-Lovejoy, D., Arrowsmith, C. H., Vedadi, M., & Schapira, M. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500467h · Cited by 99
PRMT5-mediated regulation of developmental myelination
Scaglione, A., Patzig, J., Liang, J., Frawley, R., Bok, J., Mela, A., Yattah, C., Zhang, J., Teo, S. X., Zhou, T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04863-9 · Cited by 95
PRMT5 is essential for B cell development and germinal center dynamics
Litzler, L. C., Zahn, A., Meli, A. P., Hébert, S., Patenaude, A., Methot, S. P., Sprumont, A., Bois, T., Kitamura, D., Costantino, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07884-6 · Cited by 91
Protein arginine methylation: an emerging regulator of the cell cycle
Raposo, A. E., & Piller, S. C. (2018) · Cell Division · doi:10.1186/s13008-018-0036-2 · Cited by 91
Jing, P., Zhao, N., Ye, M., Zhang, Y., Zhang, Z., Sun, J., Wang, Z., Zhang, J., & Gu, Z. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.04.019 · Cited by 86
Deng, W., Wang, Y., Ma, L., Zhang, Y. W., Ullah, S., & Xue, Y. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw041 · Cited by 86
Protein arginine methyltransferase 5: A novel therapeutic target for triple‐negative breast cancers
Vinet, M., Suresh, S., Maire, V., Monchecourt, C., Némati, F., Lesage, L., Pierre, F., Ye, M., Lescure, A., Brisson, A., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2114 · Cited by 79
Zhu, F., Guo, H., Bates, P. D., Zhang, S., Zhang, H., Nomie, K. J., Li, Y., Lü, L., Seibold, K. R., Wang, F., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0489-6 · Cited by 77
Targeting protein arginine methyltransferase 5 in cancers: Roles, inhibitors and mechanisms
Chen, Y., Shao, X., Zhao, X., Ji, Y., Liu, X., Li, P., Zhang, M., & Wang, Q. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112252 · Cited by 75
Mao, R., Shao, J., Zhu, K., Zhang, Y., Ding, H., Zhang, C., Shi, Z., Jiang, H., Sun, D., Duan, W., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00587 · Cited by 72
Webb, L., Sengupta, S., Edell, C., Piedra-Quintero, Z. L., Amici, S. A., Miranda, J. N., Bevins, M. R., Kennemer, A. A., Laliotis, G., Tsichlis, P. N., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131254 · Cited by 72
Recent advances in targeting protein arginine methyltransferase enzymes in cancer therapy
Smith, E. M., Zhou, W., Shindiapina, P., Sif, S., Li, C., & Baiocchi, R. A. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1474203 · Cited by 76
Self-citationWebb, L., Amici, S. A., Jablonski, K., Savardekar, H., Panfil, A. R., Li, L., Zhou, W., Peine, K. J., Karkhanis, V. A., Bachelder, E. M., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601702 · Cited by 70
Self-citationMi, H., Ho, W. J., Yarchoan, M. M., & Popel, A. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.892250 · Cited by 65
Protein Arginine Methyltransferases in Cardiovascular and Neuronal Function
Silva, A. C. E., Wu, C. Y., Citadin, C. T., Clemons, G. A., Possoit, H. E., Grames, M. S., Lien, C.-F., Minagar, A., Lee, R. H., Frankel, A., et al. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01850-z · Cited by 64
Holmes, B., Benavides-Serrato, A., Saunders, J. T., Landon, K. A., Schreck, A. J., Nishimura, R. N., & Gera, J. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03274-0 · Cited by 63
Sheng, Y., Wang, H., Liu, D., Zhang, C., Deng, Y., Yang, F., Zhang, T., & Zhang, C. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.11.017 · Cited by 62
Wu, Y., Wang, Z., Zhang, J., & Ling, R. (2017) · Tumor Biology · doi:10.1177/1010428317695917 · Cited by 58
Li, M., An, W., Xu, L., Lin, Y., Su, L., & Liu, X. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1064-8 · Cited by 56
Zhang, B., Dong, S., Li, Z., Li, L., Zhang, S., Chen, X., Cen, X., & Wu, Y. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0721-8 · Cited by 55
PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer
Wang, Z., Kong, J., Wu, Y., Zhang, J., Wang, T., Li, N., Fan, J., Wang, H., Zhang, J., & Ling, R. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4597-6 · Cited by 58
PRMT5/Wnt4 axis promotes lymph-node metastasis and proliferation of laryngeal carcinoma
Wang, N., Yan, H., Wu, D., Zhao, Z., Chen, X., Qian, L., Zhang, C., Wang, X., Deng, W., & Liu, X. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03064-x · Cited by 51
Medicinal chemistry strategies targeting PRMT5 for cancer therapy
Fu, S., Zheng, Q., Zhang, D., Lin, C., Ouyang, L., Zhang, J., & Chen, L. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114842 · Cited by 50
Yao, B., Zhu, S., Wei, X., Chen, M., Feng, Y., Li, Z., Xu, X., Zhang, Y., Wang, Y., Zhou, J., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01598-6 · Cited by 48
Kanda, M., Shimizu, D., Fujii, T., Tanaka, H., Shibata, M., Iwata, N., Hayashi, M., Kobayashi, D., Tanaka, C., Yamada, S., et al. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3584 · Cited by 48
Writers, Readers, and Erasers of Epigenetic Marks
Nicholson, T. B., Veland, N., & Chen, T. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800206-3.00003-3 · Cited by 49
Quan, X., Yue, W., Luo, Y., Cao, J., Wang, H., Wang, Y., & Lu, Z. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13191 · Cited by 47
Mongiardi, M. P., Savino, M., Bartoli, L., Beji, S., Nanni, S., Scagnoli, F., Falchetti, M. L., Favia, A., Farsetti, A., Levi, A., et al. (2015) · Scientific Reports · doi:10.1038/srep15494 · Cited by 46
Zhang, H., Zhang, D., Zha, Z., & Hu, C. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.09.015 · Cited by 45
PRMT5 promotes cancer cell migration and invasion through the E2F pathway
Barczak, W., Jin, L., Carr, S. M., Munro, S., Ward, S., Kanapin, A. A., Samsonova, A. A., & Thangue, N. B. L. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02771-9 · Cited by 52
Targeting Protein Arginine Methyltransferase 5 in Disease
Richters, A. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0089 · Cited by 43
Zakrzewicz, D., Didiášová, M., Krüger, M., Giaimo, B. D., Borggrefe, T., Mieth, M., Hocke, A. C., Zakrzewicz, A., Schaefer, L., Preissner, K. T., et al. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.02.021 · Cited by 43
Sepsa, A., Levidou, G., Gargalionis, A. N., Adamopoulos, C., Spyropoulou, A., Dalagiorgou, G., Thymara, I., Boviatsis, E. I., Themistocleous, M. S., Petraki, K., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0115101 · Cited by 41
Wang, Q., Xu, J., Li, Y., Huang, J., Jiang, Z., Wang, Y., Liu, L., Leung, E. L., & Yao, X. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00173 · Cited by 38
Regulation of RNA Splicing: Aberrant Splicing Regulation and Therapeutic Targets in Cancer
Kitamura, K., & Nimura, K. (2021) · Cells · doi:10.3390/cells10040923 · Cited by 38
O’Brien, S. W., Butticello, M., Thompson, C., Wilson, B. G., Wyce, A., Mahajan, V., Kruger, R. G., Mohammad, H. P., & Fedoriw, A. (2023) · BMC Cancer · doi:10.1186/s12885-023-11260-z · Cited by 36
The potential and challenges of targeting MTAP-negative cancers beyond synthetic lethality
Bray, C., Balcells, C. D., McNeish, I. A., & Keun, H. C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1264785 · Cited by 42
Shimizu, D., Kanda, M., Sugimoto, H., Shibata, M., Tanaka, H., Takami, H., Iwata, N., Hayashi, M., Tanaka, C., Kobayashi, D., et al. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.3833 · Cited by 35
Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma
Chaturvedi, N. K., Mahapatra, S., Kesherwani, V., Kling, M. J., Shukla, M., Ray, S., Kanchan, R. K., Perumal, N., McGuire, T. R., Sharp, J. G., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6291-z · Cited by 34
Splicing Dysregulation as Oncogenic Driver and Passenger Factor in Brain Tumors
Bielli, P., Pagliarini, V., Pieraccioli, M., Caggiano, C., & Sette, C. (2019) · Cells · doi:10.3390/cells9010010 · Cited by 34
Rong, D., Zhou, K., Fang, W., Yang, H. J., Zhang, Y., Shi, Q., Huang, Y., Li, J., Dong, H. F., Li, L., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00398 · Cited by 34
Discovery of Novel PRMT5 Inhibitors by Virtual Screening and Biological Evaluations
Tao, H., Yan, X., Zhu, K., & Zhang, H. (2019) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c18-00980 · Cited by 34
Stitzlein, L. M., Adams, J. T., Stitzlein, E., Dudley, R. W., & Chandra, J. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02923-7 · Cited by 32
Otani, Y., Sur, H. P., Rachaiah, G., Namagiri, S., Chowdhury, A. K., Lewis, C. T., Shimizu, T., Gangaplara, A., Wang, X., Vézina, A., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab014 · Cited by 33
Self-citationArginine Methylation in Brain Tumors: Tumor Biology and Therapeutic Strategies
Bryant, J.-P., Heiss, J. D., & Banasavadi‐Siddegowda, Y. (2021) · Cells · doi:10.3390/cells10010124 · Cited by 32
Self-citationNovel Protein Arginine Methyltransferase 8 Isoform Is Essential for Cell Proliferation
Hernandez, S. J., & Dominko, T. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25508 · Cited by 31
Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas
Park, J., & Turcan, Ş. (2019) · Cancers · doi:10.3390/cancers11101616 · Cited by 33
Prevalence of S-methyl-5′-thioadenosine Phosphorylase (MTAP) Deficiency in Human Cancer
Gorbokon, N., Wößner, N., Lennartz, M., Rico, S. D., Kind, S., Reiswich, V., Viehweger, F., Lutz, F., Fraune, C., Luebke, A. M., et al. (2024) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000002297 · Cited by 35
Zhu, K., Song, J., Tao, H., Cheng, Z., Jiang, C., & Zhang, H. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.10.026 · Cited by 30
The Where and the How of PRMT5
Koh, C. M., Bezzi, M., & Guccione, E. (2015) · Current Molecular Biology Reports · doi:10.1007/s40610-015-0003-5 · Cited by 29
Panfil, A. R., Al-Saleem, J., Howard, C. M., Mates, J. M., Kwiek, J. J., Baiocchi, R. A., & Green, P. A. (2015) · Viruses · doi:10.3390/v8010007 · Cited by 29
Self-citationAn Update on the Epigenetics of Glioblastomas
Ferreira, W. A. S., Pinheiro, D. D. R., da Costa, C. A., Rodrigues-Antunes, S., Araújo, M. D., Barros, M. B. L., Teixeira, A. C. D. S., Faro, T. A. S., Burbano, R. M. R., de Oliveira, E. H. C., et al. (2016) · Epigenomics · doi:10.2217/epi-2016-0040 · Cited by 29
Saha, K., Fisher, M. L., Adhikary, G., Grun, D., & Eckert, R. L. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx044 · Cited by 29
PRMT5 is essential for the eIF4E-mediated 5′-cap dependent translation
Lim, J.-H., Lee, Y.-M., Lee, G., Choi, Y., Lim, B. O., Kim, Y. J., Choi, D., & Park, J. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.09.033 · Cited by 29
Zhang, L., Yang, Y., Li, Y., Wang, C., Bian, C., Wang, H., & Wang, F. (2025) · Biomarker Research · doi:10.1186/s40364-025-00788-w · Cited by 28
Zhu, K., Tao, H., Song, J., Lu, J., Zhang, Y., Liu, J., Chen, Z., Jiang, C., Luo, C., & Zhang, H. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.08.021 · Cited by 26
Fan, Z., He, L., Li, M., Cao, R., Deng, M., Ping, F., Liang, X., He, Y., Wu, T., Tao, X., et al. (2020) · Neoplasia · doi:10.1016/j.neo.2020.09.004 · Cited by 28
Discovery of selective protein arginine methyltransferase 5 inhibitors and biological evaluations
Ji, S., Ma, S., Wang, W., Huang, S., Wang, T., Xiang, R., Hu, Y., Chen, Q., Li, L., & Yang, S. (2016) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12881 · Cited by 25
Amici, S. A., Osman, W., & Guerau‐de‐Arellano, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.695947 · Cited by 25
Deregulacja mechanizmów epigenetycznych w nowotworach Marta Maleszewska*,
Maleszewska, M., Wojtaś, B., & Kamińska, B. (2018) · Postępy Biochemii · doi:10.18388/pb.2018_125 · Cited by 23
Zhu, K., Shao, J., Tao, H., Yan, X., Luo, C., Zhang, H., & Duan, W. (2019) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-019-00214-y · Cited by 23
Zheng, Y., Chen, Z., Zhou, B., Chen, S., Han, L., Chen, N., Ma, Y., Xie, G., Yang, J., Nie, H., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100523 · Cited by 24
Glioblastoma-Derived Small Extracellular Vesicles: Nanoparticles for Glioma Treatment
Araujo‐Abad, S., Manresa-Manresa, A., Rodríguez-Cañas, E., Fuentes-Baile, M., García-Morales, P., Mallavia, R. M., Saceda, M., & Romero, C. D. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065910 · Cited by 23
Late Cornified Envelope Group I, a Novel Target of p53, Regulates PRMT5 Activity
Deng, Z., Matsuda, K., Tanikawa, C., Lin, J.-Y., Furukawa, Y., Hamamoto, R., & Nakamura, Y. (2014) · Neoplasia · doi:10.1016/j.neo.2014.07.008 · Cited by 22
Critical Roles of Protein Arginine Methylation in the Central Nervous System
Chang, K.-W., Gao, D., Yan, J., Lin, L., Cui, T., & Lu, S. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03465-x · Cited by 21
Zhang, B., Zhang, S., Zhu, L., Chen, X., Zhao, Y., Li, C., Zhou, J., Wang, X., Zhang, X., & Ma, N.-Q. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.10.002 · Cited by 21
Self-citationArginine methylation: the promise of a ‘silver bullet’ for brain tumours?
Samuel, S. F., Barry, A., Greenman, J., & Beltrán-Álvarez, P. (2021) · Amino Acids · doi:10.1007/s00726-020-02937-x · Cited by 20
Du, C., Li, S. W., Singh, S. X., Roso, K., Sun, M. A., Pirozzi, C. J., Yang, R., Li, J.-L., & He, Y. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0093 · Cited by 21
Chemogenomics for drug discovery: clinical molecules from open access chemical probes
Quinlan, R. B. A., & Brennan, P. E. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00016k · Cited by 18
Wang, J., Shen, S., You, J., Wang, Z., Li, Y., Chen, Y., Tuo, Y., Chen, D., Yu, H., Zhang, J., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06920-2 · Cited by 19
Hu, G., Xiu, W., Han, Y., & Wang, P. (2018) · EXCLI journal · doi:10.17179/excli2018-1719 · Cited by 18
Brown-Burke, F., Hwang, I., Sloan, S. L., Hinterschied, C., Helmig-Mason, J., Long, M., Chan, W. K., Prouty, A., Chung, J.-H., Zhang, Y., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023009906 · Cited by 17
Self-citationThe Role of the PRMT5–SND1 Axis in Hepatocellular Carcinoma
Wright, T., Wang, Y., & Bedford, M. T. (2021) · Epigenomes · doi:10.3390/epigenomes5010002 · Cited by 18
He, Q., Zhang, Y., Li, W., Chen, S., Xiong, J., Zhao, R., Yuan, K., Hu, Q., Liu, S., Gao, G., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217214 · Cited by 16
Patounas, O., Papacharalampous, I., Eckerich, C., Markopoulos, G. S., Kolettas, E., & Fackelmayer, F. O. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26373 · Cited by 16
Metadata
- Authors
- Yan, F., Alinari, L., Lustberg, M. E., Katherine Martin, L., Cordero-Nieves, H. M., Banasavadi-Siddegowda, Y., Virk, S., Barnholtz-Sloan, J., Bell, E. H., Wojton, J., Jacob, N. K., Chakravarti, A., Nowicki, M. O., Wu, X., Lapalombella, R., Datta, J., Yu, B., Gordon, K., Haseley, A., Patton, J. T., Smith, P. L., Ryu, J., Zhang, X., Mo, X., Marcucci, G., Nuovo, G., Kwon, C.-H., Byrd, J. C., Chiocca, E. A., Li, C., Sif, S., Jacob, S., Lawler, S., Kaur, B., & Baiocchi, R. A.
- Affiliations
- Case Comprehensive Cancer Center (US)
- Authors' Affiliations: 1Division of Hematology, Department of Internal Medicine; 2Division of Infectious Diseases, Department of Internal Medicine; Departments of 3Neurosurgery; 4Molecular and Cellular Biochemistry; 5Chemical Engineering; 6Statistics; 7Pathology; 8Radiation Oncology; and 9College of Pharmacy, The Ohio State University (OSU), Columbus; 10Case Comprehensive Cancer Center; and 11Department of Epidemiology and Biostatistics, CWRU School of Medicine, Cleveland, Ohio
- Brigham and Women's Hospital (US)
- Corresponding author
- Kaur, Balveen
- Baiocchi, Robert A.
- ORCID
- Venue
- Cancer Research
- Published
- 2014-03-13
- Volume
- 74
- Issue
- 6
- Pages
- 1752-1765
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC3959215
- OpenAlex
- W2109483913
- Cited by
- 180
- References
- 40
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 16 · 2023: 26 · 2022: 12 · 2021: 18 · 2020: 10 · 2019: 15 · 2018: 17 · 2017: 12 · 2016: 13 · 2015: 15 · 2014: 3
- FWCI
- 6.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (TL1TR000091)
- National Cancer Institute (R01CA150153, P30CA016058, P01CA163205)
- National Institute of General Medical Sciences (T32GM136583)
- National Institute of Neurological Disorders and Stroke (R01NS064607, R21NS071346)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer-related gene regulation
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
- Keywords
- PRMT5, protein arginine methyltransferase, glioblastoma, ST7, gene silencing, therapeutic target, prognostic factors, temozolomide, caspase-dependent apoptosis, cell migration, cell cycle arrest, patient survival, theranostic target
- MeSH terms
- Animals, Brain Neoplasms, Glioblastoma, Humans, Mice, Nude, Neoplasm Transplantation, Protein-Arginine N-Methyltransferases, Gene Expression, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Apoptosis, Mice, Knockout, Tumor Suppressor Proteins, RNA, Small Interfering, Cell Line, Tumor, Cell Proliferation, Mice, Kaplan-Meier Estimate, Gene Knockdown Techniques, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
